Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
2014 (English)In: Advances in Therapy, ISSN 0741-238X, E-ISSN 1865-8652, Vol. 31, no 4, 375-391 p.Article, review/survey (Refereed) Published
Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastrointestinal and skin-related adverse events (AEs). This review summarizes recommendations based on existing guidelines, research evidence, and consensus opinions of expert authors, with the aim of providing practicing physicians with the specific clinical information needed to educate the patient and better manage pirfenidone-related AEs with continued pirfenidone treatment. The main recommendations to help prevent and/or mitigate gastrointestinal and skin-related AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, wearing protective clothing, and applying a broad-spectrum sunscreen with high ultraviolet (UV) A and UVB protection. These measures can help optimize AE management, which is key to maintaining patients on an optimal treatment dose.
Place, publisher, year, edition, pages
2014. Vol. 31, no 4, 375-391 p.
Adverse event management, Expert opinion, Gastrointestinal events, Idiopathic pulmonary fibrosis, Photosensitivity, Pirfenidone, Respiratory, Safety, Skin-related events
Pharmacology and Toxicology
IdentifiersURN: urn:nbn:se:uu:diva-228237DOI: 10.1007/s12325-014-0112-1ISI: 000335309800001OAI: oai:DiVA.org:uu-228237DiVA: diva2:733282
Correction in: Advances in Therapy, Volume 31, Issue 5, pp 575-576 , doi: 10.1007/s12325-014-0118-82014-07-082014-07-082014-07-11Bibliographically approved